Table 4.

Currently ongoing clinical trials of redifferentiation strategy for radioiodine refractoriness in differentiated thyroid cancer

Identifier	Target	Drug	Type of Study	Enrolled Patients	Primary Outcome	Status
NCT02145143	BRAF	Vemurafenib	Pilot study, Single arm, Open label	12 (BRAF mutant, RAI-refractory thyroid cancers)	*Duration of overall response	Estimated study completion date: May, 2021
NCT04462471	BRAF, PI3K	Vemurafenib+ Copanlisib	Phase I, Single group assignment, Open label	22 (BRAF mutant, RAI-refractory thyroid cancers)	MTD	Estimated study completion date: June, 2022
NCT03244956	MEK, BRAF	Trametinib or Dabrafenib	Phase II, Parallel assignment, Open label	87 (one for patients with RAS mutation and one for patients with BRAFV600E mutation)	ORR	Estimated study completion date: December, 2022
NCT02152995	MEK	Trametinib	Phase II, Single arm, Open label	35 (RAS mutant or RAS/RAF wild-type, RAI-refractory recurrent and/or metastatic thyroid cancers)	Proportion of patients alive following treatment with trametinib and 124I, PFS, ORR, Iodine incorporation	Estimated primary completion date: June 30, 2021
ISRCTN17468602	MEK	Selumetinib	Phase II, Single arm,	80 (Differentiated thyroid cancer)	PFS	Closed (Overall trial end date: 18/01/2020)
NCT03469011	PDGFRα	Imatinib	Phase I, Sequential assignment, Open label	18 (Metastatic thyroid cancer)	Restore iodine uptake	Estimated study completion date: December 31, 2020

Abbreviations: MTD: maximum tolerated dose; ORR: objective response rate; PDGFRɑ: platelet-derived growth factor receptor-ɑ; PFS: progression-free survival; PI3K: phosphoinositide 3-kinase; RAI: radioactive iodine. * The duration of overall response is measured from the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented.